- CAR T-cell therapy is approved by FDA to treat some forms of aggressive blood cancer (e.g., refractory non-Hodgkin lymphoma, relapsed or refractory acute lymphoblastic leukemia) in patients up to age 25. How does this therapy work? Cite outcomes from clinical trials, listed in peer- reviewed publications. What are the limitations of this cellular engineering approach? What are some side-effects and how could they be overcome in future? How can we adapt that platform to treat another such condition in the humans, say solid tumors?